EPC1: A Versatile Drug Target for Various Diseases (G80314)

Target Name: EPC1

NCBI ID: G80314

EPC1

EPC1: A Versatile Drug Target for Various Diseases

EPC1 (EPC1_HUMAN), a protein that belongs to the endoplasmic reticulum (ER) transmembrane protein family, plays a critical role in various cellular processes in the human body. EPC1 is expressed in most tissues and cells, and its function is highly conserved across species.

One of the unique aspects of EPC1 is its ability to interact with various signaling molecules, including TGF-β, Wnt, and Notch. These interactions enable EPC1 to regulate various cellular processes, including cell growth, differentiation, and survival. Additionally, EPC1 has has been implicated in several diseases, including cancer, neurodegenerative diseases, and developmental disorders.

Given its prominent role in cellular signaling, EPC1 has become an attractive drug target for researchers. Many studies have investigated the potential therapeutic benefits of targeting EPC1, with the goal of developing new treatments for various diseases. In this article, we will discuss the current state of research on EPC1 as a drug target and highlight some of the most promising strategies for future research.

Current Treatments and Therapies

The most common treatment for diseases associated with EPC1 is the use of inhibitors that specifically target the protein. One such class of inhibitors is the EPC1 inhibitors, which are small molecules or antibodies that bind to EPC1 and prevent it from interacting with signaling molecules. These Inhibitors can be either agonists or antagonists, depending on their effect on the signaling pathway.

One of the most well-known EPC1 inhibitors is PF-4802667, which is a small molecule inhibitor that was developed by Pfizer. PF-4802667 is a potent inhibitor of EPC1, with a binding constant (Ki) of 8 nM for the EPC1- TGF-β interaction and 2 nM for the EPC1-Wnt interaction. PF-4802667 has been shown to be effective in preclinical studies for the treatment of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

Another EPC1 inhibitor is AC-1455, which is a peptide-conjugated drug that is targeted to the EPC1-TGF-β interface. The Ki value for AC-1455 has been reported to be 2 nM for the EPC1-TGF-β interaction and 12 nM for the EPC1-Wnt interaction. Like PF-4802667, AC-1455 has shown promise in preclinical studies for the treatment of neurodegenerative diseases.

Another approach to targeting EPC1 is the use of antibodies that specifically recognize and inhibit the protein. One such antibody is called EPC1-BL, which was developed by the company Generations. EPC1-BL is a monoclonal antibody that targets the EPC1 protein and has been shown to be effective in preclinical studies for the treatment of various diseases, including cancer.

Promising Strategies for Future Research

Despite the promising results of current treatments and therapies, there is still much to be done to fully understand the potential of EPC1 as a drug target. Here are some promising strategies for future research:

1. Further characterization of the EPC1-TGF-β interaction: More studies are needed to determine the full scope and specificity of the EPC1-TGF-β interaction, as well as the underlying mechanisms that regulate this interaction.
2. Investigation of the efficacy and safety of EPC1 inhibitors: More studies are needed to determine the efficacy of EPC1 inhibitors in treating various diseases, including cancer, neurodegenerative diseases, and developmental disorders.
3. Development of new EPC1 inhibitors: Researchers can continue to synthesize and evaluate new small molecules or antibodies that specifically target the EPC1 protein.
4. Study the long

Protein Name: Enhancer Of Polycomb Homolog 1

Functions: Component of the NuA4 histone acetyltransferase (HAT) complex, a multiprotein complex involved in transcriptional activation of select genes principally by acetylation of nucleosomal histones H4 and H2A (PubMed:14966270). The NuA4 complex plays a direct role in repair of DNA double-strand breaks (DSBs) by promoting homologous recombination (HR) (PubMed:27153538). The NuA4 complex is also required for spermatid development by promoting acetylation of histones: histone acetylation is required for histone replacement during the transition from round to elongating spermatids (By similarity). In the NuA4 complex, EPC1 is required to recruit MBTD1 into the complex (PubMed:32209463)

The "EPC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EPC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets